Stocktoria
Stereotaxis, Inc. STXS
Stereotaxis, Inc. (STXS) earns a Piotroski F-score of 4/9 (mixed financial health). It does not currently pay a dividend. FY2025 revenue was $32.4M at a -66.8% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -2.79 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 2036 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 4/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| STXS | Stereotaxis, Inc. | 4/9 | — | — | +20.3% |
| ECOR | electroCore, Inc. | 4/9 | — | — | +27.2% |
| POCI | PRECISION OPTICS CORPORATION, INC. | 3/9 | -8.27 | — | -0.1% |
| QTI | QT IMAGING HOLDINGS, INC. | 5/9 | -4.34 | — | — |
| HYPR | Hyperfine, Inc. | 4/9 | -16.31 | — | +5.2% |
| CV | CapsoVision, Inc | 2/9 | — | — | +15.3% |
| IRIX | IRIDEX CORP | 4/9 | -8.01 | — | +8.2% |
About Stereotaxis, Inc.
Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. The company offers robotic magnetic navigation (RMN) systems, such as Genesis RMN, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters through the blood vessels and chambers of the heart to treatment sites; and GenesisX RMN System, which is designed to enhance the accessibility of Robotic Magnetic Navigation by reducing the lengthy construction cycle necessary to install prior generation RMN systems. It also offers Odyssey, a Synchrony and SynX Solution offer integrated, real-time information solution to manage, control, record and share procedures across networks; and x-ray systems. In addition, the company offers disposables and other accessories, including MAGiC catheter, a robotically navigated magnetic ablation catheter designed to perform minimally invasive cardiac ablation procedures; MAGiC Sweep, a mapping catheter; QuikCAS, an automated catheter advancement single-use disposable device; iCONNECT; and V-CAS devices. Further, it provides interventional devices under the Map-iT, MAGiC, and EMAGIN brands, and other related devices. It markets its products through direct sales force, distributors, and sales agents. Stereotaxis, Inc. was incorporated in 1990 and is based in Saint Louis, Missouri.
FAQ
Is STXS financially healthy?
Stereotaxis, Inc.'s Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak).
Does STXS pay a dividend?
No, Stereotaxis, Inc. does not currently pay a dividend.
How profitable is STXS?
In FY2025, Stereotaxis, Inc. had a net margin of -66.8% and a return on equity of -160.5%.
What is the analyst price target for STXS?
The average Wall-Street price target for Stereotaxis, Inc. is $4.12, about 217.3% above the recent price, from 4 analysts (consensus: strong buy).
Is STXS a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Stereotaxis, Inc.: a Piotroski F-score of 4/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.